Comparative Pharmacology
Head-to-head clinical analysis: FLUDROCORTISONE ACETATE versus VALISONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLUDROCORTISONE ACETATE versus VALISONE.
FLUDROCORTISONE ACETATE vs VALISONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Mineralocorticoid receptor agonist; promotes sodium reabsorption and potassium excretion in renal distal tubules, increasing extracellular fluid volume. Also has glucocorticoid activity.
Betamethasone valerate is a corticosteroid that induces phospholipase A2 inhibitory proteins (lipocortins), which control the release of arachidonic acid from membrane phospholipids, thereby inhibiting prostaglandin and leukotriene synthesis. It has anti-inflammatory, antipruritic, and vasoconstrictive effects.
0.1 mg orally once daily, range 0.05-0.2 mg/day
Topical: Apply a thin layer to affected skin once or twice daily. Maximum duration: 2 weeks.
None Documented
None Documented
Terminal elimination half-life is 3.5 hours (range 2–5 h); clinical effect duration exceeds half-life due to mineralocorticoid receptor binding.
Approximately 1.7 hours after topical application; systemic half-life is short due to rapid metabolism.
Renal (80%) as inactive metabolites; less than 5% unchanged; minor biliary/fecal elimination.
Renal (primarily as metabolites, <5% unchanged); biliary/fecal elimination accounts for <10%.
Category D/X
Category C
Corticosteroid
Corticosteroid